-       Report 
- April 2023
-  80 Pages 
- Asia Pacific 
   From       €4227EUR$4,750USD£3,721GBP 
          -       Report 
- June 2022
-  58 Pages 
- North America 
   From       €1335EUR$1,500USD£1,175GBP 
          -       Report 
- November 2023
-  138 Pages 
- South Korea 
   From       €3203EUR$3,599USD£2,819GBP 
            -       Report 
- December 2022
-  142 Pages 
- Global 
   From       €3139EUR$3,528USD£2,763GBP 
      €3693EUR$4,150USD£3,251GBP 
          -       Report 
- October 2024
-  91 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
           -       Report 
- October 2024
-  98 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- August 2024
-  71 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- August 2024
-  80 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- July 2024
-  100 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
                 Sevoflurane is an anesthetic drug used in medical procedures to induce and maintain general anesthesia. It is a volatile anesthetic, meaning it is administered as a gas and is rapidly eliminated from the body. It is a halogenated ether, meaning it contains a halogen atom, such as fluorine, bonded to an ether molecule. It is a colorless, non-flammable liquid with a pleasant odor. It is commonly used in pediatric and adult patients for induction and maintenance of general anesthesia. It is also used    in combination with other anesthetic drugs to provide balanced anesthesia.
Sevoflurane is a popular anesthetic drug due to its rapid onset and offset of action, low blood solubility, and low risk of toxicity. It is also relatively inexpensive compared to other anesthetic drugs.
Some companies in the sevoflurane market include Baxter International, AbbVie, Merck & Co., and Hospira. Show Less   Read more